LCTX - Lineage Cell Therapeutics Inc
Close
0.8839
0.007 0.803%
Share volume: 442,000
Last Updated: Fri 30 Aug 2024 10:30:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.88
0.01
0.81%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-09 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-03-07 | 2024-05-09 | |
| Total revenue | 4.553 M | 2.998 M | 1.915 M | 2.386 M | 3.225 M | 1.246 M | 2.088 M | 1.444 M | |
| Cost of revenue | 215.000 K | 235.000 K | 102.000 K | 119.000 K | 127.000 K | 169.000 K | 256.000 K | 98.000 K | |
| Gross profit | 4.338 M | 2.763 M | 1.813 M | 2.267 M | 3.098 M | 1.077 M | 1.832 M | 1.346 M | |
| -36.31% | -34.38% | 25.04% | 36.66% | -65.24% | 70.10% | -26.53% | |||
| Operating expenses | 8.572 M | 8.014 M | 8.452 M | 8.909 M | 8.122 M | 7.782 M | 8.194 M | 8.007 M | |
| Selling general and admin | 5.270 M | 4.422 M | 4.347 M | 4.724 M | 4.249 M | 4.041 M | 4.288 M | 4.997 M | |
| Research and development | 3.302 M | 3.592 M | 4.105 M | 4.185 M | 3.873 M | 3.741 M | 3.906 M | 3.010 M | |
| Total expenses | 8.787 M | 8.249 M | 8.554 M | 9.028 M | 8.249 M | 7.951 M | 8.450 M | 8.105 M | |
| -6.12% | 3.70% | 5.54% | -8.63% | -3.61% | 6.28% | -4.08% | |||
| Operating income | -4.234 M | -5.251 M | -6.639 M | -6.642 M | -5.024 M | -6.705 M | -6.362 M | -6.661 M | |
| Ebit | -4.234 M | -5.251 M | -6.639 M | -6.642 M | -5.024 M | -6.705 M | -6.362 M | -6.661 M | |
| Pretax income | -6.782 M | -5.575 M | -6.362 M | -6.207 M | -5.203 M | -7.158 M | -4.714 M | -6.558 M | |
| -17.80% | 14.12% | -2.44% | -16.18% | 37.57% | -34.14% | 39.12% | |||
| Income tax | 0.000 | 541.000 K | 0.000 | -1.803 M | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -6.763 M | -6.069 M | -6.354 M | -4.372 M | -5.229 M | -7.110 M | -4.775 M | -6.542 M | |
| 10.26% | -4.70% | 31.19% | -19.60% | -35.97% | 32.84% | -37.01% | |||
| Net income | -6.763 M | -6.069 M | -6.354 M | -4.372 M | -5.229 M | -7.110 M | -4.775 M | -6.542 M | |
| 10.26% | -4.70% | 31.19% | -19.60% | -35.97% | 32.84% | -37.01% |